Exact Mass: 512.067

Exact Mass Matches: 512.067

Found 84 metabolites which its exact mass value is equals to given mass value 512.067, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

6-(Dibromomethylene)-17beta-hydroxy-androst-4-en-3-one propionate

C23H30Br2O3 (512.0562)

Cefamandole nafate

C19H17N6NaO6S2 (512.0549)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

{2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-6-yl]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid

C21H20O13S (512.0625)

{2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid

C21H20O13S (512.0625)

I-Bop

7-{3-[3-hydroxy-4-(4-iodophenoxy)but-1-en-1-yl]-7-oxabicyclo[2.2.1]heptan-2-yl}hept-5-enoic acid

C23H29IO5 (512.106)

CHLOROCYCLINONE B

C26H21ClO9 (512.0874)

Vitexin 7-O-sulfate

C21H20O13S (512.0625)

Isovitexin 7-O-sulfate

5,7,4-Trihydroxyflavone 6-C-glucoside 7-O-sulfate

C21H20O13S (512.0625)

3,5,7-Trihydroxyflavone 3-glucoside-8-sulfate

3- (beta-D-Glucopyranosyloxy) -5,7-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-8-sulfonic acid

C21H20O13S (512.0625)

Galangin 3-O-beta-D-glucoside-8-sulfonate

(-)-Galangin 3-O-beta-D-glucoside-8-sulfonate

C21H20O13S (512.0625)

1-O-galloyl-6-O-(4-hydroxy-3,5-dimethoxy)benzoyl-beta-D-glucose|1-O-galloyl-6-O-(4-hydroxy-3,5-dimethoxybenzoyl)-beta-D-glucose

C22H24O14 (512.1166)

C29H20O9

C29H20O9 (512.1107)

Napyradiomycin C2

C25H27Cl3O5 (512.0924)

(-)-hopeanol|hopeanol

C29H20O9 (512.1107)

6-sulfooxy-chrysin 7-glucopyranoside

C21H20O13S (512.0625)

O鈥樎?Sulfate-Afzelin

C21H20O13S (512.0625)

5,6,7,3,4-pentaacetoxyflavone

C25H20O12 (512.0955)

7-(3,5-dihydroxyphenoxy)-3-(2,4,6-trihydroxyphenoxy)dibenzo-p-dioxin-1,2,6,8-tetrol

C24H16O13 (512.0591)

alpha-Oxo-2,4,6-trihydroxy-3-[2-(3,4-dihydroxyphenyl)-4-oxo-5,7-dihydroxy-2,3-epoxy-3,4-dihydro-2H-1-benzopyran-3-yl]benzeneacetic acid methyl ester

C24H16O13 (512.0591)

T988|T988 A|T988A

C23H20N4O4S3 (512.0647)

Quercetin acetate

C25H20O12 (512.0955)

Peracetate Quercetin

Quercetin pentaacetate

C25H20O12 (512.0955)

relative retention time with respect to 9-anthracene Carboxylic Acid is 1.197 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.201

I-Bop

[1S-[1α,2α(Z),3β(1E,3S*),4α]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid

C23H29IO5 (512.106)

PU-H71

9H-Purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-

C18H21IN6O2S (512.0491)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents

Arbidol HCl

C22H26BrClN2O3S (512.0536)

BMS-777607

N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

C25H19ClF2N4O4 (512.1063)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164000 - c-Met-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

3,3-diethyl-2,2-oxathiacarbocyanine iodide

C25H25IN2O2 (512.0961)

bis-(2,4,6-Trimethylpyridine)iodine(I) hexafluorophosphate

C16H20F6IN2P (512.0313)

9,10-Anthracenedione,2,2-(1,3,4-oxadiazole-2,5-diyl)bis[1-amino-

C30H16N4O5 (512.1121)

2-CHLORO-N-(2-(PYRIDIN-3-YLAMINO)PYRIMIDIN-5-YL)-5-(3-(TRIFLUOROMETHYL)BENZAMIDO)BENZAMIDE

C24H16ClF3N6O2 (512.0975)

decamethonium iodide

C16H38I2N2 (512.1124)

BIS(3-ISOPROPYL-4-METHOXYPHENYL)IODONIUM TETRAFLUOROBORATE

C20H26BF4IO2 (512.1007)

2-amino-6-(4-chlorophenyl)sulfanyl-4-[1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]pyridine-3,5-dicarbonitrile

C22H17ClN6O5S (512.067)

Cromolyn sodium

Cromolyn (sodium)

C23H14Na2O11 (512.0331)

C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C29714 - Mast Cell Stabilizer COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D000893 - Anti-Inflammatory Agents > D000082142 - Mast Cell Stabilizers D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents D018926 - Anti-Allergic Agents D007155 - Immunologic Factors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Vat Red 31

C30H16N4O5 (512.1121)

Trovafloxacin Mesylate

C21H19F3N4O6S (512.0977)

A methanesulfonate (mesylate) salt prepared from equimolar amounts of trovafloxacin and methanesulfonic acid. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure. D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors

1,1,2,2-tetrakis(4-nitrophenyl)ethene

C26H16N4O8 (512.0968)

Uranium tricarbide

U2C3 (512.1016)

3-(Perfluoro-5-methylhexyl)-2-hydroxypropyl methacrylate

C14H11F15O3 (512.0469)

Ponceau SS

C22H16N4O7S2 (512.046)

5-Chloro-4-((1-(5-chloro-2-pyrimidinyl)-4-piperidinyl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)-2(1H)-pyridinone

C21H19Cl2FN4O4S (512.0488)

C.I. Acid Red 73, disodium salt

C22H16N4O7S2 (512.046)

L-lactyl-2-diphospho-5-guanosine(3-)

C13H16N5O13P2-3 (512.022)

dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-hexopyranose

C16H22N2O13P2-2 (512.0597)

5-O-{[(1S)-1-carboxylatoethoxy]phosphinato}-1-deoxy-1-(8-hydroxy-2,4-dioxo-2H-pyrimido[4,5-b]quinolin-3-id-10(4H)-yl)-D-ribitol

C19H19N3O12P-3 (512.0706)

3-ADP-glycerate(3-)

C13H16N5O13P2-3 (512.022)

(E)-7-[3-[(E)-3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid

C23H29IO5 (512.106)

2-[(2-Hydroxynaphthalen-1-yl)diazenyl]-5-[(4-sulfophenyl)diazenyl]benzene-1-sulfonic acid

C22H16N4O7S2 (512.046)

N-[4-[[3-(4-sulfamoylanilino)-2-quinoxalinyl]sulfamoyl]phenyl]acetamide

C22H20N6O5S2 (512.0937)

N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-5-methyl-N-(thiophen-2-ylmethyl)-2,1,3-benzothiadiazole-4-sulfonamide

C23H20N4O4S3 (512.0647)

N-[1-benzyl-2,4,6-trioxo-5-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl]-2,4-dichlorobenzamide

C21H13Cl2F3N4O4 (512.0266)

ustilaginoidin A dianion

C28H16O10-2 (512.0743)

(4-{(E)-[5-(4-chlorophenyl)-6-(ethoxycarbonyl)-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2(3H)-ylidene]methyl}phenoxy)acetic acid

C25H21ClN2O6S (512.0809)

N(2)-(1-hydroxy-2-oxopropyl)-GDP

C13H16N5O13P2-3 (512.022)

ustilaginoidin A(2-)

C28H16O10 (512.0743)

A phenolate anion that is the conjugate base of ustilaginoidin A, obtained by deprotonation of the two hydroxy groups at positions 5 and 5. It is the major microspecies at pH 7.3.

dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-glucose(2-)

C16H22N2O13P2 (512.0597)

A nucleotide-sugar oxoanion arising from deprotonation of the diphosphate OH groups of dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-glucose; major species at pH 7.3.

GSK-25

C24H16Cl2F2N6O (512.0731)

GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 μM for CYP2C9, CYP2D6, CYP3A4, respectively)[1].